CN1268637C - 衣原体蛋白、其基因序列及用途 - Google Patents

衣原体蛋白、其基因序列及用途 Download PDF

Info

Publication number
CN1268637C
CN1268637C CNB988118173A CN98811817A CN1268637C CN 1268637 C CN1268637 C CN 1268637C CN B988118173 A CNB988118173 A CN B988118173A CN 98811817 A CN98811817 A CN 98811817A CN 1268637 C CN1268637 C CN 1268637C
Authority
CN
China
Prior art keywords
gly
ser
chlamydia
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988118173A
Other languages
English (en)
Chinese (zh)
Other versions
CN1283108A (zh
Inventor
J·W·杰克逊
J·L·佩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Immunization Programme
Emergent Product Development Gaithersburg Inc
Original Assignee
Antex Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biologics Inc filed Critical Antex Biologics Inc
Publication of CN1283108A publication Critical patent/CN1283108A/zh
Application granted granted Critical
Publication of CN1268637C publication Critical patent/CN1268637C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/125—Gram-negative bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB988118173A 1997-10-02 1998-10-01 衣原体蛋白、其基因序列及用途 Expired - Fee Related CN1268637C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/942,596 1997-10-02
US08/942,596 US7459524B1 (en) 1997-10-02 1997-10-02 Chlamydia protein, sequence and uses thereof
US08/942596 1997-10-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2006100887769A Division CN1911960B (zh) 1997-10-02 1998-10-01 衣原体蛋白、其基因序列及用途

Publications (2)

Publication Number Publication Date
CN1283108A CN1283108A (zh) 2001-02-07
CN1268637C true CN1268637C (zh) 2006-08-09

Family

ID=25478327

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988118173A Expired - Fee Related CN1268637C (zh) 1997-10-02 1998-10-01 衣原体蛋白、其基因序列及用途
CN2006100887769A Expired - Fee Related CN1911960B (zh) 1997-10-02 1998-10-01 衣原体蛋白、其基因序列及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006100887769A Expired - Fee Related CN1911960B (zh) 1997-10-02 1998-10-01 衣原体蛋白、其基因序列及用途

Country Status (15)

Country Link
US (6) US7459524B1 (cg-RX-API-DMAC10.html)
EP (2) EP1862472A3 (cg-RX-API-DMAC10.html)
JP (1) JP2001518489A (cg-RX-API-DMAC10.html)
KR (1) KR100586569B1 (cg-RX-API-DMAC10.html)
CN (2) CN1268637C (cg-RX-API-DMAC10.html)
AR (2) AR018013A1 (cg-RX-API-DMAC10.html)
AU (1) AU752426B2 (cg-RX-API-DMAC10.html)
BR (1) BR9813841A (cg-RX-API-DMAC10.html)
CA (1) CA2305709A1 (cg-RX-API-DMAC10.html)
CO (1) CO5050400A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0004639A3 (cg-RX-API-DMAC10.html)
NZ (1) NZ503763A (cg-RX-API-DMAC10.html)
SA (1) SA99191283B1 (cg-RX-API-DMAC10.html)
WO (1) WO1999017741A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA989012B (cg-RX-API-DMAC10.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US5868735A (en) 1997-03-06 1999-02-09 Scimed Life Systems, Inc. Cryoplasty device and method
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2000066739A2 (en) * 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7731980B2 (en) * 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
ES2386386T3 (es) * 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
ITTO20050905A1 (it) * 2005-12-23 2007-06-24 Univ Degli Studi Torino Leganti sintetici capaci di legare l'ocratossina e relativi usi
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2162460A4 (en) * 2007-06-14 2012-06-06 Emergent Product Dev Gaithersburg Inc VACCINES AGAINST CHLAMYDIA INFECTIONS
US20090254588A1 (en) * 2007-06-19 2009-10-08 Zhong Li Multi-Dimensional Data Merge
WO2010005474A1 (en) * 2008-06-16 2010-01-14 Emergent Product Development Gaithersburg Inc. Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
EP2907523B1 (en) 2009-01-29 2018-03-28 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
EP2941269B1 (en) 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutic vaccines for treating herpes simplex virus type 2 infections
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4427782A (en) * 1981-03-03 1984-01-24 Caldwell Harlan D Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4935352A (en) 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0425082T3 (da) 1989-09-04 1995-07-03 Evans Medical Ltd Vacciner
US5071962A (en) 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
US5965141A (en) 1991-02-15 1999-10-12 Uab Research Foundation Epitopic regions of pneumococcal surface protein a
US5725863A (en) * 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
DE69313134T2 (de) * 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
IL107628A0 (en) 1992-11-18 1994-02-27 Calypte Inc Immunoassays for microorganisms associated with sexually transmitted diseases
DE69434221T2 (de) 1993-09-10 2006-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bindungsdomänen von Plasmodius Vivax und Plasmodium Falciparum Erythrozyten bindenden Proteinen
NZ276874A (en) 1993-11-03 1997-11-24 Pfizer Vaccine for treating chlamydia comprising a major outer membrane protein and lipopolysaccharide preparation from a chlamydia organism
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
EP0674005B1 (en) 1994-02-23 1999-06-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Non-reducing saccharide-forming enzyme, DNA encoding it, and their preparations and uses
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
EP0818681B1 (en) 1995-03-28 2003-06-04 Hitachi Chemical Co., Ltd. Chlamydia pneumoniae antigen, process for producing the same, method for assaying anti-chlamydia pneumoniae antibody by using the same, and reagent for assaying anti-chlamydia pneumoniae antibody
GB9506863D0 (en) 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
JPH09184843A (ja) * 1995-12-28 1997-07-15 Meiji Milk Prod Co Ltd クラミジア・トラコマチス感染の診断方法
US6464979B1 (en) 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
AU758004B2 (en) 1997-12-17 2003-03-13 Genset S.A. Extended cDNAs for secreted proteins
US6077693A (en) * 1998-05-14 2000-06-20 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a promonocyte associated protein
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2162460A4 (en) 2007-06-14 2012-06-06 Emergent Product Dev Gaithersburg Inc VACCINES AGAINST CHLAMYDIA INFECTIONS
JP4743455B2 (ja) 2009-05-26 2011-08-10 トヨタ自動車株式会社 燃料電池システム

Also Published As

Publication number Publication date
US7534445B2 (en) 2009-05-19
CN1911960A (zh) 2007-02-14
US6642023B1 (en) 2003-11-04
CO5050400A1 (es) 2001-06-27
SA99191283B1 (ar) 2006-04-18
HUP0004639A3 (en) 2004-10-28
CN1911960B (zh) 2012-11-07
AU752426B2 (en) 2002-09-19
EP1862472A2 (en) 2007-12-05
CN1283108A (zh) 2001-02-07
AR069600A2 (es) 2010-02-03
US7655246B2 (en) 2010-02-02
AR018013A1 (es) 2001-10-31
US20040137005A1 (en) 2004-07-15
CA2305709A1 (en) 1999-04-15
US6887843B1 (en) 2005-05-03
EP1019028A1 (en) 2000-07-19
HK1034187A1 (en) 2001-10-19
ZA989012B (en) 1999-04-12
KR20010030902A (ko) 2001-04-16
US7459524B1 (en) 2008-12-02
WO1999017741A1 (en) 1999-04-15
US20050048557A1 (en) 2005-03-03
HUP0004639A2 (hu) 2001-04-28
EP1019028A4 (en) 2002-11-20
KR100586569B1 (ko) 2006-06-02
US20040067524A1 (en) 2004-04-08
JP2001518489A (ja) 2001-10-16
US7419807B2 (en) 2008-09-02
AU9598898A (en) 1999-04-27
NZ503763A (en) 2003-01-31
BR9813841A (pt) 2000-10-03
EP1862472A3 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
CN1283108A (zh) 衣原体蛋白、其基因序列及用途
CN1222618C (zh) 卡他摩拉克菌外膜蛋白-106多肽及其基因序列和用途
JP2001518489A5 (cg-RX-API-DMAC10.html)
JP2008029344A (ja) 新規化合物
CN1261896A (zh) 诊断和预防莱姆病用的组合物的表面抗原和蛋白质
CN1294632A (zh) 得自母牛分枝杆菌的组合物及其使用方法
CN1204253C (zh) 奈瑟氏球菌乳铁蛋白结合蛋白
CN1326508A (zh) 脑膜炎奈瑟氏球菌(Neisseria meningitidis)的多核苷酸和多肽BASB033及其用途
HK1034187B (en) Chlamydia protein, gene sequence and uses thereof
HK1101081A (en) Chlamydia protein, gene sequence and uses thereof
CN1309706A (zh) 源自粘膜炎莫拉氏菌的化合物
JPH1057077A (ja) 新規化合物
CN1220701C (zh) 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途
JPH10323193A (ja) 新規化合物
JPH114697A (ja) 新規化合物
CN1745096A (zh) 卡他莫拉氏菌的交叉保护表位和其使用方法
JPH1175877A (ja) 新規化合物
JPH11180A (ja) ヒスチジンキナーゼ
JPH11178589A (ja) 新規RpoA
HK1036479A (en) Compositions derived from mycobacterium vaccae and methods for their use
HK1023511A (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
CN1402785A (zh) 新化合物
MXPA00003138A (en) I(chlamydia) protein, gene sequence and uses thereof
HK1021299B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: XINXING PRODUCT DEVELOPMENT GAITHERSBURG CO., LTD.

Free format text: FORMER NAME OR ADDRESS: NEWBORN IMMUNE SCHEME CO.,LTD.

Owner name: NEWBORN IMMUNE SCHEME CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: ANTEX BIOLOFICS INC.

CP01 Change in the name or title of a patent holder

Address after: American Maryland

Patentee after: New immunization programme

Address before: American Maryland

Patentee before: ANTEX BIOLOGICS, Inc.

Address after: American Maryland

Patentee after: Emergent Product Development Gaithersburg Inc.

Address before: American Maryland

Patentee before: New immunization programme

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060809

Termination date: 20121001